Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
Takimoto-Shimomura T, Nagoshi H, Maegawa S, Fujibayashi Y, Tsukamoto T, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Mizutani S, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Takimoto-Shimomura T, et al. Among authors: horiike s. Cancer Genomics Proteomics. 2018 May-Jun;15(3):213-223. doi: 10.21873/cgp.20080. Cancer Genomics Proteomics. 2018. PMID: 29695404 Free PMC article.
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Shimura Y, Mizutani S, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Takimoto-Shimomura T, et al. Among authors: horiike s. Invest New Drugs. 2019 Apr;37(2):210-222. doi: 10.1007/s10637-018-0623-8. Epub 2018 Jun 21. Invest New Drugs. 2019. PMID: 29931583
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG). Matsumoto Y, et al. Among authors: horiike s. Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24. Int J Hematol. 2019. PMID: 31127456 Clinical Trial.
Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.
Chinen Y, Tsukamoto T, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Tanba K, Mizuno Y, Fujibayashi Y, Kuwahara-Ota S, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Chinen Y, et al. Among authors: horiike s. Exp Hematol. 2020 Apr;84:45-53.e1. doi: 10.1016/j.exphem.2020.02.004. Epub 2020 Mar 5. Exp Hematol. 2020. PMID: 32145384 Free article.
Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Matsumura-Kimoto Y, et al. Among authors: horiike s. Cancer Med. 2020 Jul;9(14):5185-5199. doi: 10.1002/cam4.3136. Epub 2020 May 18. Cancer Med. 2020. PMID: 32420699 Free PMC article.
Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M. Kuroda J, et al. Among authors: horiike s. Mol Cancer Res. 2010 Jul;8(7):994-1001. doi: 10.1158/1541-7786.MCR-10-0040. Epub 2010 Jun 22. Mol Cancer Res. 2010. PMID: 20571063
Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia.
Kobayashi S, Taki T, Chinen Y, Tsutsumi Y, Ohshiro M, Kobayashi T, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Kobayashi S, et al. Among authors: horiike s. Genes Chromosomes Cancer. 2011 Apr;50(4):207-16. doi: 10.1002/gcc.20845. Epub 2011 Jan 13. Genes Chromosomes Cancer. 2011. PMID: 21319257
Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome.
Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Sasaki N, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Nakamura S, Taniwaki M. Mizutani S, et al. Among authors: horiike s. Acta Haematol. 2011;126(1):8-12. doi: 10.1159/000323565. Epub 2011 Mar 17. Acta Haematol. 2011. PMID: 21411984
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M. Sasaki N, et al. Among authors: horiike s. Exp Hematol. 2011 Aug;39(8):817-28.e1. doi: 10.1016/j.exphem.2011.05.002. Epub 2011 May 11. Exp Hematol. 2011. PMID: 21640157 Free article.
272 results